Study objective: There is growing evidence that regularβ
2-agonist use in patients with asthma is associated with
decreased airway caliber and increased bronchial responsiveness. The
aim of this study was to determine whether regular treatment withβ
2-agonists induces changes in lung function and
bronchial responsiveness in patients with primary ciliary
Design: A randomized, double-blind,
placebo-controlled, crossover study.
Nineteen children with primary ciliary dyskinesia.
Interventions: Subjects received inhaled salbutamol or
identical placebo (2 × 100 μg qid) for periods of 6 weeks with a
wash-out period of 4 weeks.
Measurements and results:
FEV1 was measured before and 3 weeks and 6 weeks after
salbutamol or placebo treatment. High-dose methacholine inhalation
tests were performed before and 6 weeks after each treatment. The
provocative concentration of methacholine producing a 20% fall in
FEV1 (PC20) and maximal airway narrowing
(MΔFFEV1) was measured. No significant change in
FEV1 was observed during the salbutamol or placebo periods.
No significant differences in the parameters of bronchial
responsiveness (PC20 and MΔFFEV1) were noted
as the result of either salbutamol or placebo treatment.
Conclusion: Our data have shown that salbutamol, inhaled
regularly for 6 weeks, did not cause either a decline in lung function
or an increase in bronchial responsiveness in subjects with primary